Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia (CP-CML) significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment.
Lessons to psychiatrists-in-training from the CIA’s mind-control projects
My chief resident gave me a strange look when I arrived for another day of work at the Mayo Clinic one morning. “Something you’re not
April 23, 2024